8-K filing — CITIUS ONCOLOGY, INC. (CTOR)
Filed: 2026-10-26 AccNo: 0001213900-26-112477 Size: 247 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Citius Oncology Reports Preliminary Fiscal Q4 2026 Operational Results
Citius Oncology announced a 120% increase in wholesaler shipments of its LYMPHIR immunotherapy for the fiscal fourth quarter of 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
Citius Oncology shares are trading lower after the company reported worse-than-expected Q3 sales results.
Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
HIVE Digital Technologies Ltd (NASDAQ: HIVE) rose in pre-market trading due to its subsidiary's new agreement. Other gainers include IP Strategy Holdings, INVO Fertility, My Size, Trugolf Holdings, Expion360, Skye Bioscience, Julong Holding, FIEE Inc, and Keel Infrastructure. Losers include Generation Income Properties, Barfresh Food Group, iTonic Holdings, Akanda Corp, and Reservoir Media.
Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494
Citius Oncology shares are trading higher after the company reported a 78% quarter-over-quarter growth in new institutional accounts ordering LYMPHIR.